|
| Author | Year | Number of patients (number of lesions) | Dose | Primary site | Treated site (s) | Local control | Toxicity | Remarks |
|
| Greco et al. [70] | 2011 | 103 (126) | 18–24 Gy in 1 fraction (SBRT) | Prostate, renal, and colorectal | Bone, LN, and soft tissue | 64% (82% if >22 Gy, 25% for 18–20 Gy) at 2 years | <4% grade 3 (stricture, neuritis) | |
|
| Jereczek-Fossa et al. [71] | 2009 | 14 (14) | 30 Gy in 3 fractions (Linac-CyberKnife) | Prostate | Pelvic LN | 100% at 18.6 months | No grade 3 or higher | |
|
| Casamassima et al. [73] | 2011 | 25 (25) | 30 Gy in 3 fractions | Prostate | Prostate, Pelvic LN, para-aortic LN, and mediastinal LN | 90% at 3 years | No grade 2 or higher | DFS 17% at 3 years |
|
| Jereczek-Fossa et al. [72] |
2012 | 34 (38) | 30 Gy in 5 fractions to 36 Gy in 3 fractions (CyberKnife) | Prostate | LN and bone | 88% at 16.9 months | 6% grade 3 urinary and 3% grade 3 rectal | All toxicities seen in prostate recurrence patients |
|
| Muacevic et al. [74] |
2013 | 40 (64) | 20 Gy in 1 fraction (SBRT) | Prostate | Bone | 95.5% at 2 years | No grade 3 or higher | |
|
| Berkovic et al. [75] |
2013 | 24 (29) | 50 Gy in 10 fractions (repeated SBRT) | Prostate | Bone or LN | 100% at 2 years | No grade 3 or higher | DFS of 42% at 2 years |
|
| Ahmed et al. [77] | 2013 | 17 (21) | 20 Gy in 1 fraction (SBRT) | Prostate | Bone, LN, and liver | 100% at 4.8 months | No grade 3 or higher | |
|
| Schick et al. [64] | 2013 | 50 (50) | 64 Gy (EBRT) | Prostate | Bone, LN, and visceral | — | No grade 3 or higher | BRFS, CFFS, OS of 54.5%, 58.6%, and 92%, respectively |
|
| Decaestecker et al. [76] | 2014 | 50 (70) | 50 Gy in 10 fractions or 30 Gy in 3 fractions (repeated SBRT) | Prostate | Bone and LN | 100% at 2 years | Grade 1 (14%)
Grade 2 (6%) | ADT-FS median 25 months |
|
